Adsett Roger sells $32.0M of INSMAdsett Roger 内部减持 INSM $32.0M
English Version
Insmed Incorporated (INSM) Chief Operating Officer Adsett Roger completed an open-market stock sale on August 10, 2026, selling 239,850 common shares at a per-share price of $133.27, for a total transaction value of $31,964,810. A Form 4 insider transaction filing was submitted to the U.S. SEC on August 12, 2026, and the sale represents 0.111% of INSM’s $28.7 billion market capitalization.
Specific Transaction Details
This trade is classified as an S-Sale (open-market sale) rather than an M-Exempt transaction, distinct from seven additional Form 4 filings submitted by Roger on the same August 12 date, which were all M-Exempt trades totaling 397,700 shares worth ~$8.67 million. The large-scale sale stands apart from the smaller, routine exempt trades filed concurrently.
Market Signal Context
As a core member of the company’s executive leadership team, Roger’s large open-market sale represents a material insider ownership change. Unlike the M-Exempt trades, which may fall under pre-arranged trading plans, the S-Sale is a direct, unplanned (per filing disclosure) disposition of shares, making it a more notable insider signal.
Cross-Reference Validation
This sale occurred two trading days after INSM released its Q2 2026 earnings on August 6, which beat consensus revenue estimates by $29,989,100 (actual $425,486,000 vs. consensus $395,496,900). The company’s stock rose 34% on August 7 following the earnings announcement. Additionally, fellow executive Flammer Martina, Chief Medical Officer, filed eight small Form 4 trades on August 7, with the largest single non-exempt sale totaling ~$1.13 million, far smaller than Roger’s August 10 transaction.
Signal Limitations
The Form 4 filing does not disclose whether this sale was executed under a pre-arranged 10b5-1 trading plan, so it cannot be used to infer Roger’s personal valuation of INSM, future business outlook, or underlying personal financial motivations. The data also does not provide insight into the company’s near-term operational or stock price performance.
Follow-Up Markers
Investors should monitor for additional Form 4 filings from Adsett Roger or other executive team members, as well as the timing of any subsequent insider ownership changes following INSM’s upcoming Q3 2026 earnings report.
中文版本
英矽制药（INSM）首席运营官Adsett Roger于2026年8月10日完成公开市场股票出售，共计减持239,850股INSM普通股，每股成交价133.27美元，交易总价值31,964,810美元。该笔交易的Form 4内幕交易申报文件于2026年8月12日正式提交至美国SEC，本次减持占INSM当时287亿美元市值的0.111%。
具体交易细节
本次交易属于公开市场卖出（S-Sale），而非免税减持（M-Exempt），与Roger同日提交的7笔额外Form 4申报形成区分——后者均为免税减持，合计397,700股，总价值约867万美元。此次大额减持规模显著高于同日提交的小额免税交易，属于非例行的仓位调整行为。
市场信号意义
作为公司核心管理团队成员，首席运营官的大额公开减持属于值得关注的内幕交易信号。与同日提交的免税减持不同，本次非免税公开卖出未被归类为预先安排的常规交易，因此其仓位调整的市场参考性更强。
交叉验证参考
本次减持发生在2026年8月6日发布Q2财报后的两个交易日：当季营收达4.25486亿美元，超出市场预期约2998.91万美元，公司股价于8月7日上涨34%。此外，同期公司首席医疗官Flammer Martina于8月7日提交8笔小额Form 4申报，其中最大单笔非免税减持价值约113万美元，远低于Roger本次减持规模。
信号局限性
本次Form 4申报仅披露了交易的时间、数量与价格，未提及是否基于10b5-1预先安排计划，因此无法直接推断减持动机、对公司未来估值的判断，或是否存在其他未披露的个人财务安排。该数据同样无法预测公司后续股价表现或业务动向。
后续关注要点
需持续关注Adsett Roger是否有额外的内幕交易申报，以及公司核心管理团队在INSM 2026年第三季度财报发布后的仓位变化情况。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。